TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer

TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer

Background Recombinant interleukin-2 (IL-2, aldesleukin) is an approved cancer immunotherapy but causes severe toxicities including cytokine storm and vascular leak syndrome (VLS). IL-2 promotes antitumor function of IL-2Rβ/γ+ natural killer (NK) cells and CD8+, CD4+ and gamma delta (γδ) T cells. Ho...

Full description

Bibliographic Details
Main Authors: Anne Månsson Kvarnhammar, Juha Punnonen, Enping Hong, Diana Reich, Karan Uppal, Kathy Bang, David B Rosen, Burkhardt Laufer, Thomas Knappe, Jens Jakob Karlsson, Yu-Chi Lee, Dhruv Thakar, Luis Alejandro Zúñiga, Simran Singh Sabharwal, Janne Damm Olling, Kristian Kjaergaard, Thomas Kurpiers, Meike Schnabel, Philipp Glock, Joachim Zettler, Mathias Krusch, Ana Bernhard, Stefan Heinig, Valentino Konjik, Thomas Wegge, Yvonne Hehn, Steffen Killian, Laura Viet, Josefine Runz, Frank Faltinger, Mohammad Tabrizi, Kristin Laura Abel, Vibeke Miller Breinholt, Stina M Singel, Kennett Sprogøe
Format: Article
Language:English
Published: BMJ Publishing Group 2022-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/7/e004991.full

Internet

https://jitc.bmj.com/content/10/7/e004991.full

Similar Items